Lupin receives US FDA approval for Modafinil Tablets, USP

Global pharma major Lupin announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg. The US FDA has approved Lupin’s Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD). Modafinil Tablets (RLD Provigil) had estimated annual sales of USD 70.7 million in the US (IQVIA MAT Jul 2026).   The post Lupin receives US FDA approval for Modafinil Tablets, USP appeared first on Express Pharma.